FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378746368> ?p ?o ?g. }

• W4378746368 endingPage "457" @default.
• W4378746368 startingPage "449" @default.
• W4378746368 abstract "Background: 6-mercaptopurine usage is associated with myelotoxicity and increased risk in patients carrying metabolism-related genetic variations. This study aimed to determine the frequency of candidate gene polymorphisms and their association with 6-mercaptopurine intolerance. Methods: A total of 41 patients on acute lymphoblastic leukaemia treatment were genotyped for TPMT and NUDT15 (rs116855232) alleles, and their association with dose intensity was analyzed. Results: The defective TPMT*3C allele frequency was 9.8%. The median maintenance dose intensity for TPMT*1/*3C participants was considerably lower (47%) when compared with the TPMT*1/*1 wild-type (77%), although not statistically significant. Conclusion: This is the first pharmacogenetics study carried out in a black Zimbabwean leukemia patient cohort. The high defective TPMT*3C (9.8%) allele frequency points to the potential utility of pharmacogenetics testing for safe usage of 6-mercaptopurine in this population.Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children in Zimbabwe and 6-mercaptopurine is frequently used as part of its treatment. However, 6-mercaptopurine is associated with side-effects such as severe neutropenia (a condition where you have a low number of white blood cells called neutrophils in your blood), with increased risk observed in patients carrying variants in genes involved in the metabolism of 6-mercaptopurine. Therefore, this study aimed to determine the frequency of polymorphisms in specific genes as well as their association with drug intolerance. A total of 41 patients on ALL treatment were studied. Review of treatment records was done to determine the cumulative 6-mercaptopurine dose and calculate dose intensity. Genotyping (to determine the versions of a gene a patient carries) for TPMT and NUDT15 (rs116855232) was performed and results correlated with drug dose intensity. The most frequent genotype was TPMT*1/*1, occurring in 80% of the participants. The remaining 20% were carriers with two different copies of TPMT (*1/*3C). The defective TPMT*3C variation occurred at 9.8% and none had TPMT*2, *3A, *3B or NUDT15 rs116855232 variants. Comparison analysis with dose intensity was done for 23 participants (56%) who had maintenance records available. The median dose intensity of 47% for TPMT*1/*3C participants was considerably low when compared to that of a normal TPMT*1/*1 patient, which was 77%. However, no statistically significant difference was observed between TPMT genotype and dose intensity. This is the first study in a group of leukemic Zimbabweans to investigate the frequency of TPMT and NUDT15 variants. With a high variation frequency of 9.8% for the defective TPMT*3C, pharmacogenetics testing for TPMT before treatment with 6-MP is recommended in the Zimbabwean population." @default.
• W4378746368 created "2023-05-31" @default.
• W4378746368 creator A5011859484 @default.
• W4378746368 creator A5040324386 @default.
• W4378746368 creator A5046138031 @default.
• W4378746368 creator A5050902693 @default.
• W4378746368 creator A5069116936 @default.
• W4378746368 date "2023-06-01" @default.
• W4378746368 modified "2023-09-27" @default.
• W4378746368 title "Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia" @default.
• W4378746368 cites W1872688600 @default.
• W4378746368 cites W1967589295 @default.
• W4378746368 cites W2081541637 @default.
• W4378746368 cites W2109000403 @default.
• W4378746368 cites W2116765834 @default.
• W4378746368 cites W2135506468 @default.
• W4378746368 cites W2145840251 @default.
• W4378746368 cites W2340010050 @default.
• W4378746368 cites W2515359555 @default.
• W4378746368 cites W2582497016 @default.
• W4378746368 cites W2585761567 @default.
• W4378746368 cites W2590193371 @default.
• W4378746368 cites W2605343642 @default.
• W4378746368 cites W2611433020 @default.
• W4378746368 cites W2731117318 @default.
• W4378746368 cites W2805416018 @default.
• W4378746368 cites W2900673338 @default.
• W4378746368 cites W2903466396 @default.
• W4378746368 cites W2915002766 @default.
• W4378746368 cites W2932572702 @default.
• W4378746368 cites W2948521885 @default.
• W4378746368 cites W2963843897 @default.
• W4378746368 cites W3008760290 @default.
• W4378746368 cites W3026645177 @default.
• W4378746368 cites W3030834484 @default.
• W4378746368 cites W3125652021 @default.
• W4378746368 cites W3158589578 @default.
• W4378746368 cites W3160246014 @default.
• W4378746368 cites W3192193334 @default.
• W4378746368 cites W3195969834 @default.
• W4378746368 cites W3198109324 @default.
• W4378746368 cites W4213291693 @default.
• W4378746368 cites W4213366783 @default.
• W4378746368 cites W4289526948 @default.
• W4378746368 doi "https://doi.org/10.2217/pgs-2023-0026" @default.
• W4378746368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37248698" @default.
• W4378746368 hasPublicationYear "2023" @default.
• W4378746368 type Work @default.
• W4378746368 citedByCount "0" @default.
• W4378746368 crossrefType "journal-article" @default.
• W4378746368 hasAuthorship W4378746368A5011859484 @default.
• W4378746368 hasAuthorship W4378746368A5040324386 @default.
• W4378746368 hasAuthorship W4378746368A5046138031 @default.
• W4378746368 hasAuthorship W4378746368A5050902693 @default.
• W4378746368 hasAuthorship W4378746368A5069116936 @default.
• W4378746368 hasConcept C104317684 @default.
• W4378746368 hasConcept C126322002 @default.
• W4378746368 hasConcept C135763542 @default.
• W4378746368 hasConcept C143998085 @default.
• W4378746368 hasConcept C180754005 @default.
• W4378746368 hasConcept C203014093 @default.
• W4378746368 hasConcept C2776694085 @default.
• W4378746368 hasConcept C2776760755 @default.
• W4378746368 hasConcept C2777063308 @default.
• W4378746368 hasConcept C2777173762 @default.
• W4378746368 hasConcept C2778461978 @default.
• W4378746368 hasConcept C2779134260 @default.
• W4378746368 hasConcept C2781107101 @default.
• W4378746368 hasConcept C2908647359 @default.
• W4378746368 hasConcept C2909962599 @default.
• W4378746368 hasConcept C37463918 @default.
• W4378746368 hasConcept C54355233 @default.
• W4378746368 hasConcept C55775858 @default.
• W4378746368 hasConcept C70917649 @default.
• W4378746368 hasConcept C71924100 @default.
• W4378746368 hasConcept C72563966 @default.
• W4378746368 hasConcept C86803240 @default.
• W4378746368 hasConcept C98274493 @default.
• W4378746368 hasConcept C99454951 @default.
• W4378746368 hasConceptScore W4378746368C104317684 @default.
• W4378746368 hasConceptScore W4378746368C126322002 @default.
• W4378746368 hasConceptScore W4378746368C135763542 @default.
• W4378746368 hasConceptScore W4378746368C143998085 @default.
• W4378746368 hasConceptScore W4378746368C180754005 @default.
• W4378746368 hasConceptScore W4378746368C203014093 @default.
• W4378746368 hasConceptScore W4378746368C2776694085 @default.
• W4378746368 hasConceptScore W4378746368C2776760755 @default.
• W4378746368 hasConceptScore W4378746368C2777063308 @default.
• W4378746368 hasConceptScore W4378746368C2777173762 @default.
• W4378746368 hasConceptScore W4378746368C2778461978 @default.
• W4378746368 hasConceptScore W4378746368C2779134260 @default.
• W4378746368 hasConceptScore W4378746368C2781107101 @default.
• W4378746368 hasConceptScore W4378746368C2908647359 @default.
• W4378746368 hasConceptScore W4378746368C2909962599 @default.
• W4378746368 hasConceptScore W4378746368C37463918 @default.
• W4378746368 hasConceptScore W4378746368C54355233 @default.
• W4378746368 hasConceptScore W4378746368C55775858 @default.
• W4378746368 hasConceptScore W4378746368C70917649 @default.

• next